Grant: Banting Postdoctoral Fellowship Program
University of Toronto
$140,000.00
Assembly, activation and function of BRISC deubiquitinase complexes
FY 2016-17
Summary
Our cells dispose of damaged proteins using a highly sophisticated protein degradation system. However, abnormalities in the protein degradation system are frequently observed in many diseases, including several types of cancers and auto-immune disorders. Indeed, cells possess protein machines or enzymes (ubiquitin ligases) that mediate the attachment of a small protein called ubiquitin, which is perceived as a signal that induce the destruction of unwanted proteins. On the other hand, another class of protein machines (deubiquitinases) remove ubiquitin from proteins to rescue them from destruction. In most cases, the inability to properly process damaged proteins can be attributed to the misbehavior of ubiquitin ligases or deubiquitinases.
As ubiquitin ligases and deubiquitinases are deeply implicated in human pathology, these enzymes have become very appealing targets for drug development to treat disease. Indeed, these enzymes regulate almost every signaling process in the cell and thus their manipulation can have profound impact on human physiopathology. However, these proteins are difficult to target as we do not have an extensive knowledge about their structure.
My postdoctoral project in the laboratory of Dr. Sicheri at the the Lunenfeld-Tanenbaum Research Institute, will involve a protein structure determination technology, called X-ray crystallography to understand how proteins work at the atomic level. This approach will also facilitate the discovery, characterization, and development of highly specific and potent chemical compounds that bind to these enzymes in a manner that changes their function in a desirable manner. Our ultimate goal will be to lay the foundation for the development of therapeutic molecules to treat diseases where these enzymes operate.
Department
Program
Banting Postdoctoral Fellowship Program
Recipient
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
358787
Name
Daou Salima
Region
Ontario
Country
Canada
Orgtype
Research Institution; Institution Paid
Instname2
Cancer Research
Theme2
Biomedical
Prcname2
Banting Postdoctoral Fellowships Program
Projecttitle
Assembly, activation and function of BRISC deubiquitinase complexes
Programtype2
Fellowship Programs
Orgnameinp2
University of Toronto
Cihramount2
$140,000
Cihrequipment2
$0
Programname2
Banting Postdoctoral Fellowship Program
Keyworddelim
Cellular Biology; Cryo-Electron Microscopy (Cryo-Em); Deubiquitinases; Drug Discovery; Jamm/Mpn Family Deubiquitinases; Nuclear Magnetic Resonance Spectroscopy (Nmr); Structural Biology; Ubiquitin Proteasome System (Ups); X-Ray Crystallography
Abstract
Our cells dispose of damaged proteins using a highly sophisticated protein degradation system. However, abnormalities in the protein degradation system are frequently observed in many diseases, including several types of cancers and auto-immune disorders. Indeed, cells possess protein machines or enzymes (ubiquitin ligases) that mediate the attachment of a small protein called ubiquitin, which is perceived as a signal that induce the destruction of unwanted proteins. On the other hand, another class of protein machines (deubiquitinases) remove ubiquitin from proteins to rescue them from destruction. In most cases, the inability to properly process damaged proteins can be attributed to the misbehavior of ubiquitin ligases or deubiquitinases.
As ubiquitin ligases and deubiquitinases are deeply implicated in human pathology, these enzymes have become very appealing targets for drug development to treat disease. Indeed, these enzymes regulate almost every signaling process in the cell and thus their manipulation can have profound impact on human physiopathology. However, these proteins are difficult to target as we do not have an extensive knowledge about their structure.
My postdoctoral project in the laboratory of Dr. Sicheri at the the Lunenfeld-Tanenbaum Research Institute, will involve a protein structure determination technology, called X-ray crystallography to understand how proteins work at the atomic level. This approach will also facilitate the discovery, characterization, and development of highly specific and potent chemical compounds that bind to these enzymes in a manner that changes their function in a desirable manner. Our ultimate goal will be to lay the foundation for the development of therapeutic molecules to treat diseases where these enzymes operate.
Competitiondate
201609
Approvedterm2
2 yrs 0 mth
Pinamesdelim
Daou, Salima
Approvedterm
2 ans 0 mois
Cihrcontribution2
~ $140,000~ $0~